Madrigal Pharmaceuticals, Inc. (MDGL)
542.40
-4.53
(-0.83%)
USD |
NASDAQ |
Sep 03, 16:00
542.40
0.00 (0.00%)
After-Hours: 17:45
Madrigal Pharmaceuticals Research and Development Expense (TTM) : 488.62M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 488.62M |
| March 31, 2026 | 451.53M |
| December 31, 2025 | 387.02M |
| September 30, 2025 | 296.43M |
| June 30, 2025 | 191.23M |
| March 31, 2025 | 208.35M |
| December 31, 2024 | 235.62M |
| September 30, 2024 | 280.84M |
| June 30, 2024 | 283.21M |
| March 31, 2024 | 280.86M |
| December 31, 2023 | 271.82M |
| September 30, 2023 | 271.94M |
| June 30, 2023 | 269.39M |
| March 31, 2023 | 259.41M |
| December 31, 2022 | 245.31M |
| September 30, 2022 | 227.59M |
| June 30, 2022 | 214.19M |
| March 31, 2022 | 207.32M |
| December 31, 2021 | 205.16M |
| September 30, 2021 | 205.70M |
| June 30, 2021 | 204.12M |
| March 31, 2021 | 197.18M |
| December 31, 2020 | 184.81M |
| September 30, 2020 | 156.29M |
| June 30, 2020 | 122.44M |
| Date | Value |
|---|---|
| March 31, 2020 | 93.35M |
| December 31, 2019 | 72.32M |
| September 30, 2019 | 56.28M |
| June 30, 2019 | 43.05M |
| March 31, 2019 | 32.56M |
| December 31, 2018 | 25.39M |
| September 30, 2018 | 23.03M |
| June 30, 2018 | 23.50M |
| March 31, 2018 | 25.21M |
| December 31, 2017 | 24.39M |
| September 30, 2017 | 23.40M |
| June 30, 2017 | 24.52M |
| March 31, 2017 | 19.80M |
| December 31, 2016 | 15.93M |
| September 30, 2016 | 11.18M |
| June 30, 2016 | 4.060M |
| March 31, 2016 | 18.35M |
| December 31, 2015 | 34.01M |
| September 30, 2015 | 48.89M |
| June 30, 2015 | 64.42M |
| March 31, 2015 | 66.80M |
| December 31, 2014 | 68.20M |
| September 30, 2014 | 72.53M |
| June 30, 2014 | 73.95M |
| March 31, 2014 | 73.06M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Exelixis, Inc. | 824.32M |
| Karyopharm Therapeutics, Inc. | 120.81M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |